Associations of Content and Context of Communication with Prostate-Specific Antigen Testing.

Nicholas A Alford, Manasicha Wongpaiboon, John S Luque, Cynthia M Harris, Rima H Tawk
Author Information
  1. Nicholas A Alford: Institute of Public Health, College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL 32307, USA.
  2. Manasicha Wongpaiboon: Florida State University College of Medicine, Tallahassee, FL 32304, USA.
  3. John S Luque: Institute of Public Health, College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL 32307, USA. ORCID
  4. Cynthia M Harris: Institute of Public Health, College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL 32307, USA.
  5. Rima H Tawk: Institute of Public Health, College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL 32307, USA. ORCID

Abstract

There is limited research about the content and context of communication on prostate-specific antigen (PSA) testing among men in the state of Florida. The purpose of this study is to understand how the content communication (discussion of advantages and disadvantages of PSA testing between provider and patient; provider recommendations of PSA testing) and the context of communication (continuity of care denoted by the presence of a personal doctor) influence PSA testing. Data were drawn from the Florida Behavioral Risk Factor Surveillance System. Receipt of PSA testing was the primary outcome. Multiple logistic regression analyses were used to adjust for sociodemographic, clinical, healthcare access, and lifestyle characteristics when associating the content and context of communication with PSA testing. Discussions were classified into four mutually exclusive categories: discussions of advantages and disadvantages, only advantages, only disadvantages, and no discussion. The most significant predictors for PSA testing included physician recommendation, discussions including advantages, older age, non-smoking, and having a personal doctor. Individualized PSA screening may be a pathway to reducing racial disparities in screening for prostate cancer (PCa) and, by extension, lower incidence and mortality rates. Developing a bill to create an Office of Men's Health at Health & Human Services is recommended.

Keywords

References

  1. J Clin Oncol. 2011 May 1;29(13):1736-43 [PMID: 21444863]
  2. BMJ Open. 2016 Jul 12;6(7):e011356 [PMID: 27406644]
  3. Eur Urol Focus. 2022 Nov;8(6):1568-1574 [PMID: 35811285]
  4. BMJ. 2018 Sep 5;362:k3581 [PMID: 30185545]
  5. Am J Mens Health. 2016 Nov;10(6):533-536 [PMID: 26860126]
  6. Curr Cancer Rep. 2021 Jun 15;3(1):81-94 [PMID: 33898998]
  7. Aust J Gen Pract. 2023 Mar;52(3):99-101 [PMID: 36872084]
  8. J Natl Cancer Inst. 2021 Jun 1;113(6):719-726 [PMID: 33146392]
  9. N Engl J Med. 2009 Mar 26;360(13):1310-9 [PMID: 19297565]
  10. Transl Androl Urol. 2018 Feb;7(1):4-11 [PMID: 29594014]
  11. J Nurse Pract. 2018 Oct;14(9):677-682.e2 [PMID: 31086502]
  12. Am J Epidemiol. 2016 Nov 15;184(10):720-731 [PMID: 27777219]
  13. Am J Med. 2002 Dec 1;113(8):663-7 [PMID: 12505117]
  14. Cancer. 2014 Nov 15;120(22):3519-26 [PMID: 25065910]
  15. JAMA Netw Open. 2022 May 2;5(5):e2211869 [PMID: 35576008]
  16. Am J Prev Med. 2015 Aug;49(2):259-63 [PMID: 25997905]
  17. Gastrointest Endosc Clin N Am. 2020 Jul;30(3):393-411 [PMID: 32439078]
  18. J Health Care Poor Underserved. 2022;33(1):5-19 [PMID: 35153202]
  19. CA Cancer J Clin. 2016 Jul;66(4):290-308 [PMID: 26910411]
  20. Cold Spring Harb Perspect Med. 2018 Sep 4;8(9): [PMID: 29229666]
  21. BJU Int. 2018 Mar;121(3):405-414 [PMID: 28960827]
  22. Med Decis Making. 2011 Jan-Feb;31(1):108-20 [PMID: 20484092]
  23. J Cancer Educ. 2016 Dec;31(4):693-701 [PMID: 26498649]
  24. BMJ. 2012 Jan 27;344:e256 [PMID: 22286508]
  25. Cleve Clin J Med. 2012 May;79(5):313-20 [PMID: 22550073]
  26. Am J Mens Health. 2018 Nov;12(6):1929-1936 [PMID: 29952245]
  27. N Engl J Med. 2012 Mar 15;366(11):981-90 [PMID: 22417251]
  28. Am J Mens Health. 2019 Mar-Apr;13(2):1557988319834843 [PMID: 30836815]
  29. J Urol. 2013 Aug;190(2):419-26 [PMID: 23659877]
  30. PLoS One. 2017 May 16;12(5):e0177687 [PMID: 28520820]
  31. Internet Interv. 2023 Feb 01;31:100606 [PMID: 36844795]
  32. J Cancer Educ. 2022 Oct;37(5):1460-1465 [PMID: 33689157]
  33. Nat Rev Urol. 2017 Jan;14(1):26-37 [PMID: 27995937]
  34. Am J Mens Health. 2018 Jul;12(4):751-759 [PMID: 29658371]
  35. CMAJ. 2014 Nov 4;186(16):1225-34 [PMID: 25349003]
  36. Int J Clin Pract. 2020 Feb;74(2):e13447 [PMID: 31750596]
  37. JAMA. 2018 May 8;319(18):1901-1913 [PMID: 29801017]
  38. Ann Intern Med. 2012 Jul 17;157(2):120-34 [PMID: 22801674]
  39. Cancer. 2018 Jul 1;124(13):2733-2739 [PMID: 29781117]
  40. Cancer Epidemiol Biomarkers Prev. 2017 Mar;26(3):376-382 [PMID: 28223429]

Grants

  1. U54 MD007582/NIMHD NIH HHS
  2. U54 MD 007582/NIMHD NIH HHS

MeSH Term

Male
Humans
Prostate-Specific Antigen
Mass Screening
Decision Making
Prostatic Neoplasms
Communication
Early Detection of Cancer

Chemicals

Prostate-Specific Antigen

Word Cloud

Created with Highcharts 10.0.0PSAtestingcommunicationadvantagescontentcontextdisadvantagesscreeningprostate-specificantigenFloridadiscussionproviderpersonaldoctordiscussionsracialdisparitiesprostatecancerHealthlimitedresearchamongmenstatepurposestudyunderstandpatientrecommendationscontinuitycaredenotedpresenceinfluenceDatadrawnBehavioralRiskFactorSurveillanceSystemReceiptprimaryoutcomeMultiplelogisticregressionanalysesusedadjustsociodemographicclinicalhealthcareaccesslifestylecharacteristicsassociatingDiscussionsclassifiedfourmutuallyexclusivecategories:significantpredictorsincludedphysicianrecommendationincludingolderagenon-smokingIndividualizedmaypathwayreducingPCaextensionlowerincidencemortalityratesDevelopingbillcreateOfficeMen's&HumanServicesrecommendedAssociationsContentContextCommunicationProstate-SpecificAntigenTestingguidelinestestshareddecision-making

Similar Articles

Cited By